The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
Also known as: Iron and TIBC, Iron and Total Iron Binding Capacity TIBC, TIBC
Also known as: Lipid Panel with Ratios (fasting), Lipid Profile with Ratios (fasting), Lipids
Also known as: Reverse T3, Reverse Triiodothyronine, RT3, T3 Reverse RT3 LCMSMS, Triiodothyronine Reverse
Also known as: Triiodothyronine
Also known as: Free T3, FT3, T3 Free
Also known as: T4 Thyroxine Total
Also known as: Free T4, FT4, T4 Free
Also known as: Thyroid Stimulating Hormone, Thyroid Stimulating Hormone (TSH), Thyrotropin
Also known as: B12, B12 Vitamin, Cobalamin, Cyanocobalamin, Vitamin B12 Cobalamin
Also known as: B6, B6 Vitamin, Pyridoxal, Pyridoxal Phosphate, Pyridoxal Phosphate (PLP), Vitamin B6 Pyridoxal Phosphate
The TH-3. Graves Disease panel contains 15 tests with 82 biomarkers.
Brief Description: The TH-3 Graves' Disease panel is an extensive diagnostic tool specifically designed for evaluating Graves' disease, an autoimmune disorder that often leads to hyperthyroidism. This panel combines thyroid function tests with assessments for autoimmune markers, metabolic health, and nutritional status to provide a comprehensive overview of the disease's impact on the body.
Collection Method: Blood Draw
Specimen Type: Whole Blood, Serum, and Plasma
Test Preparation: Patient should be fasting 9-12 hours prior to collection.
Patient must be restricted from alcohol and vitamins for at least 24 hours before a sample collection.
Collection should be done in the morning.
Specifc to TSH: Specimen collection after fluorescein dye angiography should be delayed for at least 3 days. For patients on hemodialysis, specimen collection should be delayed for 2 weeks.
According to the assay manufacturer Siemens: "Samples containing fluorescein can produce falsely depressed values when tested with the Advia Centaur TSH3 Ultra assay."
Healthcare providers may order the TH-3 Graves' Disease panel for individuals exhibiting symptoms of hyperthyroidism, such as rapid heartbeat, weight loss, increased appetite, and irritability, which could suggest Graves' disease. It is also useful for monitoring the disease's progression and the effectiveness of treatments. Additionally, this panel helps in evaluating the potential complications and systemic effects associated with Graves' disease.
The TH-4 Graves' Disease panel builds upon the comprehensive evaluation provided by the TH-3 panel by including additional tests for TSH Receptor Binding Antibody and Thyroid Stimulating Immunoglobulin. These tests are crucial for a more detailed assessment of Graves' disease, particularly in distinguishing it from other forms of thyroiditis and hyperthyroidism. The TH-4 panel offers a deeper insight into the autoimmune mechanisms underlying Graves' disease, making it an invaluable tool for complex cases where a nuanced understanding of the disease is necessary for effective management.
The TH-3 Graves' Disease panel is designed to diagnose and manage Graves' disease by assessing thyroid function and detecting the presence of autoimmune markers. It also helps in identifying and managing potential complications such as osteoporosis, cardiovascular diseases, and diabetes, which can be associated with or exacerbated by hyperthyroidism.
Healthcare professionals utilize the results of the TH-3 Graves' Disease panel to diagnose Graves' disease, assess the severity of hyperthyroidism, and evaluate the effectiveness of treatment. The comprehensive nature of the panel allows for the identification and management of complications, ensuring a holistic approach to patient care.
The TH-3 Graves' Disease panel provides a thorough assessment of Graves' disease, offering critical insights into thyroid function, autoimmune status, and the broader health impacts of thyroid dysfunction. By combining thyroid function tests with assessments for autoimmune markers, metabolic health, and nutritional status, this panel enables healthcare providers to develop targeted treatment strategies, addressing the complexities of Graves' disease and enhancing patient care.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.